Abstract. The association of chronic myeloid leukemia (CML) with other myeloproliferative neoplasms (MPNs), in particular with the V617F mutation in the Janus kinase 2 (JAK2) gene, is very uncommon, and there are only a few cases reported in the literature. In the present study, the case of a 73-year-old man with CML and persistent thrombocytosis, is reported. The patient achieved a complete cytogenetic response and major molecular response (MR) with imatinib. The patient presented JAK2 V617F mutation, and bone marrow morphology was consistent with essential thrombocythemia. The patient was treated with imatinib and hydroxyurea to control the platelet count, and maintains complete MR with imatinib upon 10 years of follow-up. Although rare, the association of breakpoint cluster region-Abelson rearrangement and JAK2 V617F mutation should be investigated in patients with MPN, since both genetic anomalies may be present at diagnosis or may emerge during treatment, and require different therapeutic approaches.
Introduction
Myeloproliferative neoplasms (MPNs) correspond to a clonal proliferation of hematopoietic cells, resulting in expansion of ≥1 lineages (1) . Molecular markers aid to characterize these disorders, and are useful for diagnosis and follow-up of MPNs, since they enable the detection of minimal residual disease, such as breakpoint cluster region-Abelson (BCR-ABL) rearrangement in chronic myeloid leukemia (CML) (1) . The Janus kinase 2 (JAK2) V617F mutation is present in 95% of patients with polycythemia vera (PV) and in ~50% of patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (MF) (2) (3) (4) (5) . The association of CML with other forms of MPN, in particular with the JAK2 V617F mutation, is very uncommon, and there are limited cases reported in the literature (6-8). Pieri et al (9) performed a screening of 314 patients with CML and identified 8 cases (2.55%) with concomitant JAK2 V617F mutation.
Despite the rarity of the concomitant detection of BCR-ABL and JAK2 V617F mutation, it is of great importance to recognize and investigate this association, particularly when the disease has an unusual course and the diagnosis of other MPNs may have practical therapeutic consequences. Therefore, in the present study, the case of a patient diagnosed with CML, in whom an ET with JAK2 V617F mutation was detected during the course of CML follow-up, is reported.
Case report
In March 2003, a 73-year-old male patient was referred to the Hematology and Hemotherapy Center of the University of Campinas (Campinas, Brazil) for a hematological evaluation, due to leukocytosis detected in a routine exam. The patient had no clinical symptoms, and presented a white blood cell count of 49.4x10 9 cells/l [normal range, 5.2-12.4x10 9 cells/l; 2% eosinophils (normal range, 0-7%), 4.0% basophils (normal range, 0-1.5%), 1% blasts (normal range, 0%) and 2% promyelocytes (normal range, 0%)], a platelets count of 607.0x10 9 platelets/l (normal range, 150-450x10 9 /l) and hemoglobin levels of 12.2 g/dl (normal range, 13.5-17.5 g/dl). Diagnosis of CML was confirmed by conventional cytogenetic analysis, using the Giemsa-trypsin-Wright stain banding technique, which revealed the presence of the translocation t(9;22)(q34;q11) in 20/20 metaphases examined, and by reverse transcription-polymerase chain reaction (RT-PCR), which detected the BCR-ABL rearrangement (b3a2) (10) .
In consequence, the patient was treated with interferon alfa-2a (6 The patient did not achieve a normal platelet count, despite increasing the dose of imatinib to 700 mg/day, but achieved complete cytogenetic remission 6 months later. However, his platelet count increased progressively. Therefore other causes of thrombocytosis were investigated. Ferritin levels were normal and the patient showed increased prostate-specific antigen (PSA) levels (6.7 ng/ml; normal range, 0-4 ng/ml), which suggested prostate cancer. Prostate cancer was diagnosed by prostate biopsy. The patient was treated with local radiotherapy with complete remission. Despite the normalization observed in the PSA levels, the thrombocytosis persisted. In November 2006, the patient achieved a major molecular response (MR) in BCR-ABL levels, but platelets counts remained increased (622x10 9 platelets/l). To further investigate whether other MPNs were involved, the JAK2 V617F mutation was investigated and detected by restriction fragment length polymorphism analysis, as described previously (3), and confirmed by direct Sanger sequencing. The bone marrow biopsies conducted at the time of diagnosis and following treatment for CML were reanalyzed, (Figs. 1  and 2, respectively) . The post-treatment biopsy displayed global hypercellularity, increased myeloid:erythroid ratio and hyperplasia of atypical megakaryocytes, with no fibrosis. The morphology of the megakaryocytes was consistent with ET.
The imatinib dose was then decreased to 400 mg/day, as the thrombocytosis was associated with ET and not due to resistant CML. Since then, hydroxyurea (500 mg/day; oral; Hydrea; Bristol Myers-Squibb, New York City, NY, USA), has been administered concomitantly to control thrombocytosis. In the last follow-up, in December 2015, >10 years following the start of imatinib treatment, the patient maintains a complete cytogenetic response and a deep molecular response [MR 4.5, according to the international scale (11)], in the BCR-ABL transcripts levels detected by RT-PCR, using a previously described technique (12) . No thrombotic or hemorrhagic events has occurred.
Discussion
The association of JAK2 mutations and BCR-ABL rearrangement is infrequent, and was recently reported in association with MF (6, 7, 13, 14) and PV (8, 15, 16) . In a previous report by the present authors, the presence of the JAK2 V617F mutation in CML was reported to be rare, with the present case being the only one detected among 55 cases of CML analyzed (17).
Bee et al (8) reported a case of PV with JAK2 V617F mutation and BCR-ABL rearrangement at diagnosis. In that report, the patient presented a decrease in V617F alleles when the burden of BCR-ABL messenger RNA increased, and reappearance of V617F clones following the administration of imatinib. A similar case was reported by Ursuleac et al (16) , where a patient with PV developed CML following 7 years of PV diagnosis. Wahlin et al (18) described a case of ET with emergence of CML during treatment with hydroxyurea. A recent study by Mizutani et al (19) reported the emergence of CML during treatment for ET in a patient following 9 years of diagnosis. By contrast, Véronèse et al (6) reported a case of CML developing ET upon achieving BCR-ABL major MR, similarly to the present findings. In that case, the JAK2 clone was present at low levels at CML diagnosis, while in the present patient, the bone marrow histology was consistent with ET when the mutation was detected, although molecular data regarding the JAK2 mutation was not available at the time of diagnosis.
In conclusion, the present report emphasizes that the presence of persistent or increasing thrombocytosis in CML, which is not responsive to treatment, should always be further investigated. Bone marrow histology may be useful to exclude other malignant diseases or to confirm other MPNs. In the present case, JAK2 V617F mutation analysis was determinant in the final characterization of ET associated with CML. Molecular characterization of MPN at the time of diagnosis is necessary to establish a correct diagnosis and to detect concomitant clones. Although rare, the association of ET with CML may be identified at diagnosis or may appear during treatment, and may require to alter the therapeutic approach.
